Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Mayer, Erica L.; Dueck, Amylou C.; Martín, Miguel; Rubovszky, Gábor; Burstein, Harold J.; Bellet-Ezquerra, M.; Miller, Kathy D.; Zdenkowski, Nicholas; Winer, Eric P.; Pfeiler, Georg; Goetz, Matthew P.; Ruíz‐Borrego, Manuel; Anderson, D. Mark; Nowecki, Zbigniew; Loibl, Sibylle; Moulder, Stacy L.; Ring, Alistair; Fitzal, Florian; Traina, Tiffany A.; Chan, Arlene; Rugo, Hope S.; Lemieux, Julie; Henao, Fernando; Lyss, Alan P.; Novoa, Silvia Antolín; Wolff, Antonio C.; Vetter, Marcus; Egle, Daniel; Morris, Patrick G.; Mamounas, Eleftherios P.; Gil-Gil, Miguel; Prat, Aleix; Fohler, Hannes; Filho, Otto Metzger; Schwarz, Magdalena; Dufrane, Carter; Fumagalli, Debora; Theall, Kathy Puyana; Lu, Dongrui R.; Bartlett, Cynthia Huang; Koehler, Maria; Fesl, Christian; DeMichele, Angela; Gnant, Michael

doi:10.1016/s1470-2045(20)30642-2

Cited by 187 publications

(153 citation statements)

References 31 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…Interestingly the recommendations from 2020 have not been changed. With regard to the adjuvant use of CDK4/6 inhibitors, three studies have been published (PENELOPE-B, PALLAS, and monarchE) [62-64]. But none of these drugs have a label in the adjuvant setting yet.…”

Section: Adjuvant Endocrine Therapymentioning

confidence: 99%

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021

et al. 2021

Self Cite

View full text Add to dashboard Cite

Section: Adjuvant Endocrine Therapymentioning

confidence: 99%

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…The PALOMA-2 trial in the first-line advanced BC setting, patients faced a similar palbociclib regimen and schedule, and the discontinuation rate was as low as 9% [9,10,13]. However toxicities and severe adverse events reported in PALLAS were similar in kind and incidence to the PALOMA-2 and PALOMA-3 [27]. The only difference between these trials is related to the management of neutropenia, as repeated grade 3 asymptomatic neutropenia required permanent treatment discontinuation.…”

Section: Discussionmentioning

confidence: 99%

“…The PALLAS study included pre-and postmenopausal women or men with stage II (stage IIA limited to a maximum of 1000 patients) or stage III early invasive BC J o u r n a l P r e -p r o o f -- [27]. A total of 5,760 patients were recruited from September 2015 to November 2018.…”

Section: Cdk4/6 Inhibitors In Adjuvant Therapy For Early Bcmentioning

confidence: 99%

The role of CDK4/6 inhibitors in early breast cancer

et al. 2021

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“… 75 Despite 43.5% of patients included in this trial were premenopausal, no data have been reported so far on the incidence of post-treatment amenorrhea (and the follow-up of the trial is too short to assess this outcome). While palbociclib has not shown a beneficial effect in the early setting, 76 results of the adjuvant ribociclib trial are awaited.…”

Section: Gonadotoxicity Of Breast Cancer Treatments – Chemotherapymentioning

confidence: 99%

Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women

Martelli¹,

Latocca²,

Ruelle³

et al. 2021

BCTT

View full text Add to dashboard Cite

Over the last several decades, improvements in breast cancer treatment have contributed to increased cure rates for women diagnosed with this malignancy. Consequently, great importance should be paid to the long-term side effects of systemic therapies. For young women (defined as per guideline ≤40 years at diagnosis) who undergo chemotherapy, one of the most impactful side effects on their quality of life is premature ovarian insufficiency (POI) leading to fertility-related problems and the side effects of early menopause. Regimens, type, and doses of chemotherapy, as well as the age of patients and their ovarian reserve at the time of treatment are major risk factors for treatment-induced POI. For these reasons, childbearing desire and preservation of ovarian function and/or fertility should be discussed with all premenopausal patients before planning the treatments. This manuscript summarizes the available fertility preservation techniques in breast cancer patients, the risk of treatment-induced POI with different anticancer treatments, and the possible procedures to prevent it. A special focus is paid to the role of oncofertility counseling, as a central part of the visit in this setting, during which the patient should receive all the information about the potential consequences of the disease and of the proposed treatment on her future life.

show abstract

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Cited by 187 publications

References 31 publications

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021

The role of CDK4/6 inhibitors in early breast cancer

Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women

Contact Info

Product

Resources

About